- Home
- FTHM vs KPRX Comparison
FTHM vs KPRX Comparison
Compare FTHM & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | KPRX |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 10.6M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FTHM | KPRX |
|---|---|---|
| Price | $0.20 | $2.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 11.4K |
| Earning Date | 11-10-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $9.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.18 | $1.76 |
| 52 Week High | $1.78 | $2.91 |
Technical Indicators
Market Signals| Indicator | FTHM | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 26.90 | 26.13 |
| Support Level | N/A | $1.94 |
| Resistance Level | $0.92 | $2.72 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 51.24 | 2.45 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.